+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Oral Insulin"

Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025 - Product Thumbnail Image

Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025

  • Report
  • April 2020
  • 119 Pages
  • Global
From
Insulin Delivery Devices Market - Forecasts from 2019 to 2024 - Product Thumbnail Image

Insulin Delivery Devices Market - Forecasts from 2019 to 2024

  • Report
  • November 2019
  • 118 Pages
  • Global
From
Loading Indicator

The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy. Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more